November 16, 2018
There is confusion as the focus is short-term with some or none near or long-term expectation
Risk is not always diminished as time rolls forward
There is just too much fluctuation and investors get tired and more skeptical of risk adjusted prognoses
I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors in the perception of sector vulnerabilities and strengths – it’s more than opinion, the facts and truth need to be recognized!
A trusted source of factual reporting!
November 16, 2018
Q3/18 financial results is a scorecard of (AKA) earnings of 45 covered companies
37 of 45 by 11/16The current LPS (loss per share) or net income, cash positio, "runways" and correlation of "street" expectations - it's a reflection of this universe's investing "status"
Investors can gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.
November 15, 2018
IBB rallies +2.19% as uniQure NV (QURE) rocks +$8.13 or +35.66% reporting that all three patients enrolled in the study achieved and sustained therapeutic levels of Factor IX (FIX) activity at six weeks after a single administration of AMT-061
Quarterly financial results: Mesoblast (MESO +$0.17 before reporting)
Who is defining the metrics for investors?
Some have stated, “I am the “weatherman” of the sector; forecasting and presenting conditions of the sector in a given period.”
November 16, 2018
Q3/18 financial results is a scorecard of (AKA) earnings of 45 covered companies 37 of 45 by 11/16 The current LPS (loss per share) or net income, cash positio, "runways" and correlation of "street" expectations - it's a reflection of this universe's investing "status" Investors can gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.
November 9, 2018
Post reporting their Q’s; snapshots of LPS (loss-per-share) and net incomes - follow the bouncing share prices … A breakdown of reporting “figures” and commentary including Thursday’s closing numbers,: Adverum Biotechnologies (ADVM +$0.05), Histogenics (HSGX +$0.01), BioTime (NTSEMKT: BTX -$0.11), Applied Genetic Technologies (AGTC +$0.21), Intrexon (XON -$0.12), BioLife Solutions (BLFS +$0.16), Caladrius Bioscience (CLBS +$0.32), Pluristem (PSTI -$0.01), Sangamo Therapeutics (SGMO -$0.58), Stemline Therapeutics (STML -$0.36), Organovo Holdings (ONVO) and Biostage (BSTG -$0.10) Ben Graham used to talk about the stock market being a cross between a voting machine and a weighing machine The market is still voting on Friday ...
November 8, 2018
Post Wednesday’s Q3/18 reporting – there are more downs and a few ups; ALNY (-$3.27), CRSP (-$0.37), EDIT (+1.26), OSIR (+$0.45, RGNX (-$4.57), SAGE (+$2.71, VYGR (-$1.92), VSTM (-$0.03) and EDIT (+$1.31) In the midst of a market rally, there is still pain … During “earning’s” season, traders vote by buying and selling shares, and in the short run; the trades are motivated by those meeting “street” expectation versus LPS (loss-per-share) as compared to net income.
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
7 hours 10 min ago
Regenerative Medicine Earnings Scorecard - Q3/18 - to date
7 hours 12 min ago
RegMed Investors’ (RMi) pre-open: enduring a bumpy market path
© 2018 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
